Basic Information
RNALocate ID: | RLID:11000712 |
RNA Symbol: | hsa-miR-19a-3p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-19a-3p |
RNA ID: | miRBase:MIMAT0000073 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 22211110 |
Tissue/Cell Line: | Breast milk |
Method: | Next-generation RNA sequencing |
The expression profile of selected miRNAs in breast milk exosomes. Originally published in Int J Biol Sci. Zhou Q, et al, 2012. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | Distribution and characterization of miRNAs in breast milk exosomes. (A) Distribution of pre-miRNAs. Out of 1,424 pre-miRNAs deposited in miRBase 17.0 (blue circle), 87 (6.11%) pre-miRNAs have been designated as immune-related pre-miRNAs based on annotation in the Pathway Central database (SABiosciences, MD, USA). Immune-related pre-miRNAs (59 of 452, 13.05%) are enriched in breast milk exosomes (red circle). χ2 test: Number of immune-related miRNAs and others detected in breast milk exosomes compared with the total entries in miRBase 17.0. (B) Top ten most highly expressed unique miRNAs. Plot of the unique miRNAs (starting from the miRNA with the highest counts, x-axis) versus their cumulative % of the total counts from 602 unique miRNAs detected in breast milk exosomes for each small RNA library. Values are means ± s.d. The dashed horizontal line at 62.3% represents the level of the top ten unique miRNAs and the % of individual miRNAs is marked by the gray line. (C-E) The expression profile of selected miRNAs in breast milk exosomes. (C) 59 immune-related pre-miRNAs; (D) miR-17-92 cluster and paralogous clusters, and (E) ten well-characterized tissue-specific pre-miRNAs. Data are collected from Figure 2. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001278 | Cytoplasm | Colon cancer cells | 20864815 |
RLID:01001279 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001280 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001281 | Nucleolus | Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001282 | Nucleus | Neural progenitor cells | 21363885 |
RLID:11000710 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11000711 | Exosome | Renal cancer cells | 21670082 |
RLID:11000713 | Exosome | Brain tissue | 23382797 |
RLID:11000714 | Exosome | Plasma | 23663360 |
RLID:11000715 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11000716 | Exosome | Human esophageal cancer cell line (EC9706) | 25184951 |
RLID:11000717 | Exosome | Colon cancer cell line (LIM1863) | 25330373 |
RLID:11000718 | Exosome | Cerebrospinal fluid | 25420022 |
RLID:11000719 | Extracellular Vesicle | Liposarcoma cell lines (Lipo246|Lipo863|LPS141)|Preadipocytes | 28588009 |
RLID:11000720 | Extracellular vesicle | HEK-293T cells | 22849433 |
RLID:11000721 | Microvesicle | Seminal plasma | 23539611 |
RLID:11000722 | Microvesicle | Follicular fluid | 23666971 |
RLID:11000723 | Microvesicle | Cerebrospinal fluid | 24797360 |
RLID-D:11000010 | Exosome | B lymphoblastoid cells|Colon tissue|Endothelial cells|Lymphoma tissue | |
RLID-D:11000272 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-19a-3p | Splenic marginal zone lymphoma | MNDR-E-MI-25274 |
MNDR | hsa-miR-19a-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-25275 |
MNDR | hsa-miR-19a-3p | Oral squamous cell carcinoma | MNDR-E-MI-25276 |
MNDR | hsa-miR-19a-3p | Large cell neuroendocrine cancer | MNDR-E-MI-25277 |
MNDR | hsa-miR-19a-3p | Follicular cleaved lymphoma | MNDR-E-MI-25278 |
MNDR | hsa-miR-19a-3p | Medulloblastoma | MNDR-E-MI-25279 |
MNDR | hsa-miR-19a-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-25280 |
MNDR | hsa-miR-19a-3p | Spinocerebellar ataxia type 1 | MNDR-E-MI-25281 |
MNDR | hsa-miR-19a-3p | Autism spectrum disorder | MNDR-E-MI-25282 |
MNDR | hsa-miR-19a-3p | Lymphoma | MNDR-E-MI-25283 |
MNDR | hsa-miR-19a-3p | Lymphoma non-hodgkin | MNDR-E-MI-25284 |
MNDR | hsa-miR-19a-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-25285 |
MNDR | hsa-miR-19a-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-25286 |
MNDR | hsa-miR-19a-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-25287 |
MNDR | hsa-miR-19a-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-25288 |
MNDR | hsa-miR-19a-3p | Her2-receptor positive breast cancer | MNDR-E-MI-25289 |
MNDR | hsa-miR-19a-3p | Breast cancer luminal | MNDR-E-MI-25290 |
MNDR | hsa-miR-19a-3p | Niemann-pick disease type c | MNDR-E-MI-25291 |
MNDR | hsa-miR-19a-3p | Lymphoblastic lymphoma | MNDR-E-MI-25292 |
MNDR | hsa-miR-19a-3p | Thyroid carcinoma anaplastic | MNDR-E-MI-25293 |
MNDR | hsa-miR-19a-3p | Prostate cancer | MNDR-E-MI-25294 |
MNDR | hsa-miR-19a-3p | Gastric cancer | MNDR-E-MI-25295 |
MNDR | hsa-miR-19a-3p | Gastric lymphoma | MNDR-E-MI-25296 |
MNDR | hsa-miR-19a-3p | Alzheimer disease | MNDR-E-MI-25297 |
MNDR | hsa-miR-19a-3p | Intracranial aneurysm | MNDR-E-MI-25298 |
MNDR | hsa-miR-19a-3p | Bladder cancer | MNDR-E-MI-25299 |
MNDR | hsa-miR-19a-3p | Esophageal carcinoma | MNDR-E-MI-25300 |
MNDR | hsa-miR-19a-3p | Dysautonomia familial | MNDR-E-MI-25301 |
MNDR | hsa-miR-19a-3p | Head and neck cancer | MNDR-E-MI-25302 |
MNDR | hsa-miR-19a-3p | Leukemia | MNDR-E-MI-25303 |
MNDR | hsa-miR-19a-3p | Huntington disease | MNDR-E-MI-25304 |
MNDR | hsa-miR-19a-3p | Cardiovascular disease | MNDR-E-MI-25305 |
MNDR | hsa-miR-19a-3p | Moyamoya disease | MNDR-E-MI-25306 |
MNDR | hsa-miR-19a-3p | Lung cancer | MNDR-E-MI-25307 |
MNDR | hsa-miR-19a-3p | Parkinson disease | MNDR-E-MI-25308 |
MNDR | hsa-miR-19a-3p | Machado-joseph disease | MNDR-E-MI-25309 |
MNDR | hsa-miR-19a-3p | Niemann-pick disease | MNDR-E-MI-25310 |
MNDR | hsa-miR-19a-3p | Basal-like breast cancer | MNDR-E-MI-25311 |
MNDR | hsa-miR-19a-3p | Congenital heart disease | MNDR-E-MI-25312 |
MNDR | hsa-miR-19a-3p | Neuroendocrine neoplasia | MNDR-E-MI-25313 |
MNDR | hsa-miR-19a-3p | Pancreatic cancer | MNDR-E-MI-25314 |
MNDR | hsa-miR-19a-3p | Melanoma | MNDR-E-MI-25315 |
MNDR | hsa-miR-19a-3p | Rectum adenocarcinoma | MNDR-E-MI-25316 |
MNDR | hsa-miR-19a-3p | Nephroblastoma | MNDR-E-MI-25317 |
MNDR | hsa-miR-19a-3p | Colon cancer | MNDR-E-MI-25318 |
MNDR | hsa-miR-19a-3p | Colon adenocarcinoma | MNDR-E-MI-25319 |
MNDR | hsa-miR-19a-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-25320 |
MNDR | hsa-miR-19a-3p | Familial ovarian cancer | MNDR-E-MI-25321 |
MNDR | hsa-miR-19a-3p | Prostate adenocarcinoma | MNDR-E-MI-25322 |
MNDR | hsa-miR-19a-3p | Thyroid adenomas | MNDR-E-MI-25323 |
MNDR | hsa-miR-19a-3p | Carcinoma ductal breast | MNDR-E-MI-25324 |
MNDR | hsa-miR-19a-3p | Glioblastoma | MNDR-E-MI-25325 |
MNDR | hsa-miR-19a-3p | Astrocytoma | MNDR-E-MI-25326 |
MNDR | hsa-miR-19a-3p | Glioma | MNDR-E-MI-25327 |
MNDR | hsa-miR-19a-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-25328 |
MNDR | hsa-miR-19a-3p | Osteosarcoma | MNDR-E-MI-25329 |
MNDR | hsa-miR-19a-3p | Liposarcoma | MNDR-E-MI-25330 |
MNDR | hsa-miR-19a-3p | Cervical adenocarcinoma | MNDR-E-MI-25331 |
MNDR | hsa-miR-19a-3p | Gastric adenocarcinoma | MNDR-E-MI-25332 |
MNDR | hsa-miR-19a-3p | Cervical squamous cell carcinoma | MNDR-E-MI-25333 |
MNDR | hsa-miR-19a-3p | Lung squamous cell carcinoma | MNDR-E-MI-25334 |
MNDR | hsa-miR-19a-3p | Lung adenocarcinoma | MNDR-E-MI-25335 |
MNDR | hsa-miR-19a-3p | Adrenocortical cancer | MNDR-E-MI-25336 |
MNDR | hsa-miR-19a-3p | Thyroid carcinoma | MNDR-E-MI-25337 |
MNDR | hsa-miR-19a-3p | Bladder urothelial carcinoma | MNDR-E-MI-25338 |
MNDR | hsa-miR-19a-3p | Carcinoma renal cell | MNDR-E-MI-25339 |
MNDR | hsa-miR-19a-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-25340 |
MNDR | hsa-miR-19a-3p | Renal clear cell carcinoma | MNDR-E-MI-25341 |
MNDR | hsa-miR-19a-3p | Cholangiocarcinoma | MNDR-E-MI-25342 |
MNDR | hsa-miR-19a-3p | Esophageal cancer | MNDR-E-MI-25343 |
MNDR | hsa-miR-19a-3p | Lung small cell carcinoma | MNDR-E-MI-25344 |
MNDR | hsa-miR-19a-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-25345 |
MNDR | hsa-miR-19a-3p | Notch-induced t-cell acute lymphoblastic leukemia | MNDR-E-MI-25346 |
MNDR | hsa-miR-19a-3p | Cowden disease | MNDR-E-MI-25347 |
MNDR | hsa-miR-19a-3p | Breast invasive carcinoma | MNDR-E-MI-25348 |
MNDR | hsa-miR-19a-3p | Hepatocellular carcinoma | MNDR-E-MI-25349 |
MNDR | hsa-miR-19a-3p | Familiar ovarian carcinoma | MNDR-E-MI-25350 |
MNDR | hsa-miR-19a-3p | B-cell lymphoma | MNDR-E-MI-25351 |
MNDR | hsa-miR-19a-3p | Rheumatoid arthritis | MNDR-E-MI-25352 |
MNDR | hsa-miR-19a-3p | T-cell leukemia | MNDR-E-MI-25353 |
MNDR | hsa-miR-19a-3p | Malignant pleural mesothelioma | MNDR-E-MI-25354 |
MNDR | hsa-miR-19a-3p | Cervical carcinoma | MNDR-E-MI-25355 |
MNDR | hsa-miR-19a-3p | Retinoblastoma | MNDR-E-MI-25356 |
MNDR | hsa-miR-19a-3p | Neuroblastoma | MNDR-E-MI-25357 |
MNDR | hsa-miR-19a-3p | Barrett's adenocarcinoma | MNDR-E-MI-25358 |
MNDR | hsa-miR-19a-3p | Hodgkin lymphoma | MNDR-E-MI-25359 |
MNDR | hsa-miR-19a-3p | Ulcerative colitis | MNDR-E-MI-25360 |
MNDR | hsa-miR-19a-3p | Burkitt lymphoma | MNDR-E-MI-25361 |
MNDR | hsa-miR-19a-3p | Lymphosarcoma | MNDR-E-MI-25362 |
MNDR | hsa-miR-19a-3p | Crohn disease | MNDR-E-MI-25363 |
MNDR | hsa-miR-19a-3p | Tonsil cancer | MNDR-E-MI-25364 |
MNDR | hsa-miR-19a-3p | Psoriasis | MNDR-E-MI-25365 |
MNDR | hsa-miR-19a-3p | Acute myelogenous leukemia | MNDR-E-MI-25366 |
MNDR | hsa-miR-19a-3p | Colorectal cancer | MNDR-E-MI-25367 |
MNDR | hsa-miR-19a-3p | Nasopharynx carcinoma | MNDR-E-MI-25368 |
MNDR | hsa-miR-19a-3p | Acute myocardial infarction | MNDR-E-MI-25369 |
MNDR | hsa-miR-19a-3p | Multiple myeloma | MNDR-E-MI-25370 |
MNDR | hsa-miR-19a-3p | Esophageal squamous cell carcinoma | MNDR-E-MI-25371 |
MNDR | hsa-miR-19a-3p | Ependymoma | MNDR-E-MI-25372 |
MNDR | hsa-miR-19a-3p | Nasopharyngeal cancer | MNDR-E-MI-25373 |
MNDR | hsa-miR-19a-3p | Prostatic neoplasms | MNDR-E-MI-25374 |
MNDR | hsa-miR-19a-3p | Pseudorabies | MNDR-E-MI-25375 |
MNDR | hsa-miR-19a-3p | Aids dementia complex | MNDR-E-MI-25376 |
MNDR | hsa-miR-19a-3p | Epstein-barr virus infections | MNDR-E-MI-25377 |
MNDR | hsa-miR-19a-3p | Cerebral hemorrhage traumatic | MNDR-E-MI-25378 |
MNDR | hsa-miR-19a-3p | Arsenic poisoning | MNDR-E-MI-25379 |
MNDR | hsa-miR-19a-3p | Chronic pain | MNDR-E-MI-25380 |
MNDR | hsa-miR-19a-3p | Stroke lacunar | MNDR-E-MI-25381 |
MNDR | hsa-miR-19a-3p | Barrett's carcinogenesis | MNDR-E-MI-25382 |
MNDR | hsa-miR-19a-3p | Breast cancer her3+ negative | MNDR-E-MI-25383 |
MNDR | hsa-miR-19a-3p | Duke A | MNDR-E-MI-25384 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABCA1 | Homo sapiens | RR00022102 |
TOP